[The effect of antianaphylaxis drugs on specific IgE and eosinophil in serum of patients with allergic rhinitis].
OBJECTIVE
To study the roles of leukotriene and histamine in the pathogenesis of allergic rhinitis and to compare the efficacy between leukotriene receptor antagonist and antihistamine by mensurating specific IgE in serum and eosinophil in peripheral blood and nose secretion of patients with allergic rhinitis respectively.


METHODS
The patients were randomly divided into two groups and administrated montelukast sodium and loratadine respectively for two weeks. The specific IgE in serum and eosinophil in peripheral blood and nose secretion smear of patients were detected and then the state was evaluated by patients themselves and doctors.


RESULTS
After treatment the level of specific IgE in serum and eosinophil count in peripheral blood and nose secretion smear of patients were significantly lower than that before treatment (P < 0.05); There were no significant differences in the change of the level of specific IgE in serum and eosinophil count in peripheral blood and nose secretion smear between two groups after treatment (P > 0.05).


CONCLUSIONS
Treating patients with allergic rhinitis with montelukast sodium and loratadine were of similar effect. Histamine and leukotriene are both important inflammatory factors in the pathogenesis of allergic rhinitis and both play roles by affecting eosinophil accumulation and activation and by decreasing the formation of specific IgE. Leukotriene receptor antagonist is a new drug to treat allergic rhinitis.
Liu
Xiaoling
X
Department of Otolaryngology, People's Hospital, Beijing University, Beijing 100044, China.
Xing
Zhimin
Z
Gao
Zhihong
Z
D000085:Acetates / Q000627:therapeutic use*; D000328:Adult; D003521:Cyclopropanes; D004804:Eosinophils; D005260:Female; D039563:Histamine H1 Antagonists, Non-Sedating / Q000627:therapeutic use*; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood*; D020024:Leukotriene Antagonists / Q000627:therapeutic use*; D017336:Loratadine / Q000627:therapeutic use*; D008297:Male; D011804:Quinolines / Q000627:therapeutic use*; D006255:Rhinitis, Allergic, Seasonal / Q000097:blood / Q000188:drug therapy*; D013440:Sulfides
D000085:Acetates; D003521:Cyclopropanes; D039563:Histamine H1 Antagonists, Non-Sedating; D020024:Leukotriene Antagonists; D011804:Quinolines; D013440:Sulfides; D007073:Immunoglobulin E; D017336:Loratadine; C093875:montelukast